한글목차

파킨슨병의 동향과 예측

세계의 파킨슨병 시장은 2024-2030년의 CAGR이 6.1%로, 2030년까지 추정 88억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 고령화율의 상승, 진단 기술의 진보, 신흥 국가에서 헬스케어 지출의 증가입니다. 세계의 파킨슨병 시장은 carbidopa-levodopa, 도파민 아고니스트, MAO-B 저해제, COMT 저해제, 항콜린제 시장에 비즈니스 기회가 있으며, 미래가 기대됩니다.

파킨슨병 시장 인사이트

Lucintel에서는 입수 용이성으로 인해 예측 기간 중에도 소매 약국이 최대 부문을 유지할 것으로 예측하고 있습니다.

북미는 많은 수의 중요한 참가자, 높은 가처분소득, 높은 헬스케어 비용, 이 지역의 확립된 의료제도로 인해 예측 기간 중에도 최대 지역을 유지할 것입니다.

아래 11개의 주요 질문에 답변하고 있습니다. :

• Q.1.시장 부문 중 가장 유망하고 고성장인 기회는 무엇인가?
• Q.2.향후 성장이 가속하는 부문과 이유는?
• Q.3.향후 성장이 가속할 것으로 생각되는 지역과 이유는?
• Q.4.시장 역학에 영향을 미치는 주요 요인은 무엇인가? 시장에서 주요 과제와 비즈니스 리스크는?
• Q.5.이 시장에서 비즈니스 리스크와 경쟁의 위협은?
• Q.6.이 시장에서 새로운 동향과 이유는?
• Q.7.시장에서 고객의 수요 변화에는 어떤 것이 있는가?
• Q.8.이 시장에서 새로운 개발과 개발을 선도하고 있는 기업은?
• Q.9.이 시장의 주요 기업은? 주요 기업은 사업 성장을 위해 어떤 전략적 구상을 진행시키고 있는가?
• Q.10.이 시장에서 경쟁 제품은 무엇이며, 재료 및 제품의 대체에 의한 시장 점유율 하락의 위협은 어느 정도인가?
• Q.11.과거 5년간 어떤 M&A가 시행되고, 업계에 어떤 영향을 미쳤는가?

목차

제1장 주요 요약

제2장 세계의 파킨슨병 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 2018-2030년의 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 파킨슨병 시장의 동향(2018-2023년)과 예측(2024-2030년)
• 약제 클래스별 세계의 파킨슨병 시장
  • Carbidopa-Levodopa
  • 도파민 아고니스트
  • MAO-B저해제
  • COMT 저해제
  • 항콜린제
  • 기타
• 유통 채널별 세계의 파킨슨병 시장
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제4장 2018-2030년의 지역별 시장 동향과 예측 분석

• 지역별 세계의 파킨슨병 시장
• 북미의 파킨슨병 시장
• 유럽 파킨슨병 시장
• 아시아태평양의 파킨슨병 시장
• 기타 지역의 파킨슨병 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상의 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 약제 클래스별 세계의 파킨슨병 시장의 성장 기회
  • 유통 채널별 세계의 파킨슨병 시장의 성장 기회
  • 지역별 세계의 파킨슨병 시장의 성장 기회
• 세계의 파킨슨병 시장의 새로운 동향
• 전략적 분석
  • 신제품의 개발
  • 세계의 파킨슨병 시장의 능력 확대
  • 세계의 파킨슨병 시장에서의 합병, 인수, 합병사업
  • 인증과 라이선싱

제7장 유력 기업의 기업 개요

• Cerevel Therapeutics
• Novartis
• Teva Pharmaceutical Industries
• Merck & Co.
• GlaxoSmithKline
• AbbVie
• H. Lundbeck

영문목차

Parkinson Disease Trends and Forecast

The future of the global parkinson disease market looks promising with opportunities in the carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and anticholinergics markets. The global parkinson disease market is expected to reach an estimated $8.8 billion by 2030 with a CAGR of 6.1% from 2024 to 2030. The major drivers for this market are rising aging population, advances in diagnostic technologies, and increasing healthcare expenditure in emerging economies.

A more than 150-page report is developed to help in your business decisions.

Parkinson Disease by Segment

The study includes a forecast for the global parkinson disease by drug class, distribution channel, and region.

Parkinson Disease Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

• Carbidopa-Levodopa
• Dopamine Agonists
• Mao-B Inhibitors
• Comt Inhibitors
• Anticholinergics
• Others

Parkinson Disease Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Parkinson Disease Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Parkinson Disease Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies parkinson disease companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the parkinson disease companies profiled in this report include-

• Cerevel Therapeutics
• Novartis
• Teva Pharmaceutical Industries
• Merck & Co.
• GlaxoSmithKline
• AbbVie
• H. Lundbeck

Parkinson Disease Market Insights

Lucintel forecasts that retail pharmacy will remain the largest segment over the forecast period due to ease of availbility.

North America will remain the largest region over the forecast period due to large number of important participants, high disposable income, high costs for healthcare, and an established healthcare system in this area.

Features of the Global Parkinson Disease Market

Market Size Estimates: Parkinson disease market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Parkinson disease market size by drug class, distribution channel, and region in terms of value ($B).

Regional Analysis: Parkinson disease market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug class, distribution channel, and regions for the parkinson disease market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the parkinson disease market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the parkinson disease market size?

Answer: The global parkinson disease market is expected to reach an estimated $8.8 billion by 2030.

Q2. What is the growth forecast for parkinson disease market?

Answer: The global parkinson disease market is expected to grow with a CAGR of 6.1% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the parkinson disease market?

Answer: The major drivers for this market are rising aging population, advances in diagnostic technologies, and increasing healthcare expenditure in emerging economies.

Q4. What are the major segments for parkinson disease market?

Answer: The future of the global parkinson disease market looks promising with opportunities in the carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and anticholinergics markets.

Q5. Who are the key parkinson disease market companies?

Answer: Some of the key parkinson disease companies are as follows:

• Cerevel Therapeutics
• Novartis
• Teva Pharmaceutical Industries
• Merck & Co.
• GlaxoSmithKline
• AbbVie
• H. Lundbeck

Q6. Which parkinson disease market segment will be the largest in future?

Answer: Lucintel forecasts that retail pharmacy will remain the largest segment over the forecast period due to ease of availbility.

Q7. In parkinson disease market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to large number of important participants, high disposable income, high costs for healthcare, and an established healthcare system in this area.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the parkinson disease market by drug class (carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, anticholinergics, and others), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Parkinson Disease Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Parkinson Disease Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Parkinson Disease Market by Drug Class
  • 3.3.1: Carbidopa-Levodopa
  • 3.3.2: Dopamine Agonists
  • 3.3.3: MAO-B Inhibitors
  • 3.3.4: COMT Inhibitors
  • 3.3.5: Anticholinergics
  • 3.3.6: Others
• 3.4: Global Parkinson Disease Market by Distribution Channel
  • 3.4.1: Hospital Pharmacy
  • 3.4.2: Retail Pharmacy
  • 3.4.3: Online Pharmacy

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Parkinson Disease Market by Region
• 4.2: North American Parkinson Disease Market
  • 4.2.2: North American Parkinson Disease Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
• 4.3: European Parkinson Disease Market
  • 4.3.1: European Parkinson Disease Market by Drug Class: Carbidopa-Levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, and Others
  • 4.3.2: European Parkinson Disease Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
• 4.4: APAC Parkinson Disease Market
  • 4.4.1: APAC Parkinson Disease Market by Drug Class: Carbidopa-Levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, and Others
  • 4.4.2: APAC Parkinson Disease Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
• 4.5: ROW Parkinson Disease Market
  • 4.5.1: ROW Parkinson Disease Market by Drug Class: Carbidopa-Levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, and Others
  • 4.5.2: ROW Parkinson Disease Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Parkinson Disease Market by Drug Class
  • 6.1.2: Growth Opportunities for the Global Parkinson Disease Market by Distribution Channel
  • 6.1.3: Growth Opportunities for the Global Parkinson Disease Market by Region
• 6.2: Emerging Trends in the Global Parkinson Disease Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Parkinson Disease Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Parkinson Disease Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Cerevel Therapeutics
• 7.2: Novartis
• 7.3: Teva Pharmaceutical Industries
• 7.4: Merck & Co.
• 7.5: GlaxoSmithKline
• 7.6: AbbVie
• 7.7: H. Lundbeck